New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini(University of Pavia), Giampaolo Merlini(University of Pavia), Efstathios Kastritis(National and Kapodistrian University of Athens), Shaji Kumar(Mayo Clinic), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Philip N. Hawkins(The Royal Free Hospital), Meletios Α. Dimopoulos(Korea University), Angela Dispenzieri(Mayo Clinic), Stefan Schönland(Heidelberg University), Ashutosh Wechalekar(University College Hospital), Catherine Klersy(Policlinico San Matteo Fondazione), Ute Hegenbart(Heidelberg University), Raymond L. Comenzo(Tufts Medical Center), Morie A. Gertz(Medical University of South Carolina)
Cited by 965
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k